Destiny Pharma reports progress on clinical assets
Clinical-stage biotechnology company Destiny Pharma said in a year-end update on Thursday that its primary focus remained on realising the full potential of its XF-73 Nasal asset.
Stay updated with breaking news from Clinical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Clinical-stage biotechnology company Destiny Pharma said in a year-end update on Thursday that its primary focus remained on realising the full potential of its XF-73 Nasal asset.
By Kelvin McDonald of Whakaata Maori How many whānau can say they have walked the length of Aotearoa at least once in their lifetime, let alone four times?...
QU Human Nutrition students acquire advanced clinical skills
A Christchurch -based medicinal marijuana company is leading New Zealand’s first clinical trial testing medicinal cannabis as a substitute for pain and sleep...
By the time Amanda Stern was in her mid-40s, she no longer suffered from clinical depression . Her panic attacks, which had started in childhood, were mostly...